Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Phase of Trial: Phase I/II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs FLX-475 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Advanced breast cancer; Cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors FLX Bio
- 05 Nov 2018 According to a FLX Bio media release, FLX Bio Announces Clinical Trial Collaboration Agreement with Merck for this study.
- 27 Sep 2018 According to a FLX Bio media release, first patient has been treated in this trial.
- 14 Sep 2018 Status changed from planning to recruiting.